US633410A
(en)
|
1898-09-22 |
1899-09-19 |
George A Ames |
Ice-cutter.
|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
IL47062A
(en)
|
1975-04-10 |
1979-07-25 |
Yeda Res & Dev |
Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
US4665077A
(en)
|
1979-03-19 |
1987-05-12 |
The Upjohn Company |
Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
WO1981001145A1
(en)
|
1979-10-18 |
1981-04-30 |
Univ Illinois |
Hydrolytic enzyme-activatible pro-drugs
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
FI102355B1
(fi)
|
1988-02-11 |
1998-11-30 |
Bristol Myers Squibb Co |
Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
|
IL85746A
(en)
|
1988-03-15 |
1994-05-30 |
Yeda Res & Dev |
Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
|
FI891226A
(fi)
|
1988-04-28 |
1989-10-29 |
Univ Leland Stanford Junior |
Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
|
WO1990005144A1
(en)
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
WO1990008187A1
(en)
|
1989-01-19 |
1990-07-26 |
Dana Farber Cancer Institute |
Soluble two domain cd2 protein
|
ES2062519T5
(es)
|
1989-03-21 |
2003-07-16 |
Immune Response Corp Inc |
Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t.
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
JP3072330B2
(ja)
|
1989-07-19 |
2000-07-31 |
ジ・イミューン・レスポンス・コーポレーション |
自己免疫疾患および悪性疾患の治療のためのt細胞リセプターペプチド
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
JP3951062B2
(ja)
|
1991-09-19 |
2007-08-01 |
ジェネンテック・インコーポレーテッド |
少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用
|
US5362852A
(en)
|
1991-09-27 |
1994-11-08 |
Pfizer Inc. |
Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
PL174494B1
(pl)
|
1992-11-13 |
1998-08-31 |
Idec Pharma Corp |
Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
CA2173150C
(en)
|
1993-10-01 |
2004-11-30 |
Kyoichi Sakakibara |
Novel peptide derivatives
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5798100A
(en)
|
1994-07-06 |
1998-08-25 |
Immunomedics, Inc. |
Multi-stage cascade boosting vaccine
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
GB2315067B
(en)
|
1996-07-11 |
2000-02-16 |
Pharmacia Spa |
Morpholinyl anthracycline derivatives
|
DE69729843T2
(de)
|
1996-11-28 |
2005-08-25 |
Kaneka Corp. |
Verfahren zur Herstellung eines (Meth)acrylpolymers mit endständiger Hydroxylgruppe und dieses Polymer
|
DE69830901T2
(de)
|
1997-05-02 |
2006-05-24 |
Genentech Inc., San Francisco |
ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
ATE296315T1
(de)
|
1997-06-24 |
2005-06-15 |
Genentech Inc |
Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
US6602677B1
(en)
|
1997-09-19 |
2003-08-05 |
Promega Corporation |
Thermostable luciferases and methods of production
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
JP4460155B2
(ja)
|
1997-12-05 |
2010-05-12 |
ザ・スクリプス・リサーチ・インステイチユート |
マウス抗体のヒト化
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
ATE458007T1
(de)
|
1998-04-20 |
2010-03-15 |
Glycart Biotechnology Ag |
Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
|
CA2340091C
(en)
|
1998-08-11 |
2013-02-05 |
Idec Pharmaceuticals Corporation |
Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
|
GB9818731D0
(en)
|
1998-08-27 |
1998-10-21 |
Univ Portsmouth |
Compounds
|
ATE320436T1
(de)
|
1998-08-27 |
2006-04-15 |
Spirogen Ltd |
Dimere pyrrolobenzodiazepine
|
DE69942727D1
(de)
|
1998-11-09 |
2010-10-14 |
Biogen Idec Inc |
Chimärer anti-CD20 Antikörper, Rituxan, zur Verwendung in der Behandlung der chronischen lymphatischen Leukemie
|
EP2386574A3
(en)
|
1999-01-15 |
2012-06-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP3031917A1
(en)
|
1999-04-09 |
2016-06-15 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
CA2385347C
(en)
|
1999-10-04 |
2009-12-15 |
Medicago Inc. |
Method for regulating transcription of foreign genes
|
CA2388245C
(en)
|
1999-10-19 |
2012-01-10 |
Tatsuya Ogawa |
The use of serum-free adapted rat cells for producing heterologous polypeptides
|
IL149809A0
(en)
|
1999-12-15 |
2002-11-10 |
Genentech Inc |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
PT1242438E
(pt)
|
1999-12-29 |
2007-02-28 |
Immunogen Inc |
Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
|
IL151853A0
(en)
|
2000-04-11 |
2003-04-10 |
Genentech Inc |
Multivalent antibodies and uses therefor
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
WO2002031140A1
(fr)
|
2000-10-06 |
2002-04-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Cellules produisant des compositions d'anticorps
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
MXPA03004793A
(es)
|
2000-11-30 |
2004-12-03 |
Medarex Inc |
Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
WO2003026577A2
(en)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-amidobenzylethers in drug delivery agents
|
EP1443961B1
(en)
|
2001-10-25 |
2009-05-06 |
Genentech, Inc. |
Glycoprotein compositions
|
AU2002363939A1
(en)
|
2001-11-20 |
2003-06-10 |
Seattle Genetics, Inc. |
Treatment of immunological disorders using anti-cd30 antibodies
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
WO2003085102A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
|
US20050031613A1
(en)
|
2002-04-09 |
2005-02-10 |
Kazuyasu Nakamura |
Therapeutic agent for patients having human FcgammaRIIIa
|
AU2003236018A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
|
US20040110704A1
(en)
|
2002-04-09 |
2004-06-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells of which genome is modified
|
US20040132140A1
(en)
|
2002-04-09 |
2004-07-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
US7691568B2
(en)
|
2002-04-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Antibody composition-containing medicament
|
NZ556507A
(en)
|
2002-06-03 |
2010-03-26 |
Genentech Inc |
Synthetic antibody phage libraries
|
CA2494105C
(en)
|
2002-07-31 |
2013-04-02 |
Seattle Genetics, Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
US20050180972A1
(en)
|
2002-07-31 |
2005-08-18 |
Wahl Alan F. |
Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
ATE499116T1
(de)
|
2002-08-16 |
2011-03-15 |
Immunogen Inc |
Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
ES2633311T3
(es)
|
2002-12-16 |
2017-09-20 |
Genentech, Inc. |
Variantes de inmunoglobulina y usos de las mismas
|
WO2004065416A2
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
EP1608664B1
(en)
|
2003-03-31 |
2009-01-28 |
Council of Scientific and Industrial Research |
Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
|
US7755007B2
(en)
|
2003-04-17 |
2010-07-13 |
K&H Manufacturing, Inc |
Heated pet mat
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
BRPI0411276A
(pt)
|
2003-06-05 |
2006-08-01 |
Genentech Inc |
métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
|
NZ543635A
(en)
|
2003-06-25 |
2008-05-30 |
Crucell Holland Bv |
Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML
|
GB0321295D0
(en)
|
2003-09-11 |
2003-10-15 |
Spirogen Ltd |
Synthesis of protected pyrrolobenzodiazepines
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
AU2004280065A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
|
ATE516288T1
(de)
|
2003-10-22 |
2011-07-15 |
Us Gov Health & Human Serv |
Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
|
ME03330B
(me)
|
2003-11-05 |
2019-10-20 |
Roche Glycart Ag |
Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
WO2005082023A2
(en)
|
2004-02-23 |
2005-09-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
GB0404577D0
(en)
|
2004-03-01 |
2004-04-07 |
Spirogen Ltd |
Pyrrolobenzodiazepines
|
US7528126B2
(en)
|
2004-03-09 |
2009-05-05 |
Spirogen Limited |
Pyrrolobenzodiazepines
|
AU2005230848B9
(en)
|
2004-03-31 |
2011-06-02 |
Genentech, Inc. |
Humanized anti-TGF-beta antibodies
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
US7521541B2
(en)
|
2004-09-23 |
2009-04-21 |
Genetech Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
EP1870459B1
(en)
|
2005-03-31 |
2016-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
WO2006114115A1
(de)
|
2005-04-26 |
2006-11-02 |
Trion Pharma Gmbh |
Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
|
US8219149B2
(en)
|
2005-06-29 |
2012-07-10 |
Nokia Corporation |
Mobile communication terminal
|
US8871720B2
(en)
|
2005-07-07 |
2014-10-28 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
|
EP3498289A1
(en)
|
2005-07-07 |
2019-06-19 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
JP5686953B2
(ja)
|
2005-10-11 |
2015-03-18 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハー |
交差種特異的(cross−species−specific)抗体を含む組成物および該組成物の使用
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
RS52060B
(en)
|
2006-01-25 |
2012-04-30 |
Sanofi |
CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES
|
WO2007110205A2
(en)
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
US20070292936A1
(en)
|
2006-05-09 |
2007-12-20 |
Genentech, Inc. |
Binding polypeptides with optimized scaffolds
|
NZ596865A
(en)
|
2006-06-12 |
2013-07-26 |
Emergent Product Dev Seattle |
Single-chain multivalent binding proteins with effector function
|
US20090182127A1
(en)
|
2006-06-22 |
2009-07-16 |
Novo Nordisk A/S |
Production of Bispecific Antibodies
|
ME00581B
(me)
|
2006-07-18 |
2011-12-20 |
Sanofi Aventis |
Antagonisticna antitijela za tretman kancera polje pronalaska
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
ES2432792T5
(es)
|
2007-04-03 |
2023-01-16 |
Amgen Res Munich Gmbh |
Dominio de unión a CD3-épsilon específico de especies cruzadas
|
AU2008234020B2
(en)
|
2007-04-03 |
2013-02-07 |
Amgen Research (Munich) Gmbh |
Cross-species-specific CD3-epsilon binding domain
|
WO2008119566A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
DK2019104T3
(da)
|
2007-07-19 |
2013-12-16 |
Sanofi Sa |
Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf
|
WO2009051974A1
(en)
*
|
2007-10-17 |
2009-04-23 |
Nuvelo, Inc. |
Antibodes to cll-1
|
US9308257B2
(en)
|
2007-11-28 |
2016-04-12 |
Medimmune, Llc |
Protein formulation
|
AU2008343347A1
(en)
|
2007-12-21 |
2009-07-09 |
Genentech, Inc. |
Crystallization of anti-CD20 antibodies
|
EP2235064B1
(en)
|
2008-01-07 |
2015-11-25 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
WO2009099741A1
(en)
|
2008-02-01 |
2009-08-13 |
Genentech, Inc. |
Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
|
EP2303332B1
(en)
|
2008-07-15 |
2014-12-31 |
Genentech, Inc. |
Anthracycline conjugates, process for their preparation and their use as antitumor compounds
|
US20100189727A1
(en)
|
2008-12-08 |
2010-07-29 |
Tegopharm Corporation |
Masking Ligands For Reversible Inhibition Of Multivalent Compounds
|
JP5977522B2
(ja)
|
2009-02-05 |
2016-08-24 |
イミュノジェン・インコーポレーテッド |
新規ベンゾジアゼピン誘導体
|
PE20120877A1
(es)
|
2009-04-01 |
2012-08-06 |
Genentech Inc |
ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
|
AU2010234334B2
(en)
|
2009-04-08 |
2014-10-09 |
Deutsches Krebsforschungszentrum |
Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
|
MX2011014008A
(es)
|
2009-06-26 |
2012-06-01 |
Regeneron Pharma |
Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
US20130129723A1
(en)
|
2009-12-29 |
2013-05-23 |
Emergent Product Development Seattle, Llc |
Heterodimer Binding Proteins and Uses Thereof
|
LT2519543T
(lt)
|
2009-12-29 |
2016-10-10 |
Emergent Product Development Seattle, Llc |
Heterodimerus rišantys baltymai ir jų panaudojimas
|
WO2011103076A1
(en)
|
2010-02-16 |
2011-08-25 |
Medlmmune, Llc |
Hsa-related compositions and methods of use
|
SI2528625T1
(sl)
|
2010-04-15 |
2013-11-29 |
Spirogen Sarl |
Pirolobenzodiazepini in njihovi konjugati
|
CN110066339A
(zh)
|
2010-04-20 |
2019-07-30 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
MX346731B
(es)
|
2010-04-23 |
2017-03-30 |
Genentech Inc * |
Producción de proteínas heteromultiméricas.
|
WO2011143545A1
(en)
|
2010-05-14 |
2011-11-17 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
CN114246952A
(zh)
|
2010-06-08 |
2022-03-29 |
基因泰克公司 |
半胱氨酸改造的抗体和偶联物
|
ES2402254T3
(es)
|
2010-09-30 |
2013-04-30 |
Heidelberg Pharma Ag |
Conjugados de amatoxinas con ligadores mejorados
|
ES2758994T3
(es)
|
2010-11-05 |
2020-05-07 |
Zymeworks Inc |
Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
|
ES2842937T3
(es)
|
2010-11-10 |
2021-07-15 |
Amgen Res Munich Gmbh |
Prevención de efectos adversos provocados por dominios de unión específicos de CD3
|
PT2647707T
(pt)
|
2010-11-30 |
2018-11-15 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de toxicidade
|
ES2533710T3
(es)
|
2010-12-02 |
2015-04-14 |
Nerviano Medical Sciences S.R.L. |
Proceso para la preparación de derivados de morfolinil antraciclina
|
EP2497499A1
(en)
|
2011-03-10 |
2012-09-12 |
Heidelberg Pharma GmbH |
Amatoxin-conjugates with improved linkages
|
AU2012235758B2
(en)
|
2011-03-25 |
2015-05-07 |
Ichnos Sciences SA |
Hetero-dimeric immunoglobulins
|
KR101614195B1
(ko)
|
2011-03-29 |
2016-04-20 |
로슈 글리카트 아게 |
항체 Fc 변이체
|
CA2832389A1
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
RS58765B1
(sr)
|
2011-05-21 |
2019-06-28 |
Macrogenics Inc |
Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
|
EP2578230A1
(en)
|
2011-10-04 |
2013-04-10 |
Trion Pharma Gmbh |
Removal of Tumor Cells from Intraoperative Autologous Blood Salvage
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
BR112014009050B1
(pt)
|
2011-10-14 |
2022-06-21 |
Medimmune Limited |
Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
|
CA2861816C
(en)
|
2011-12-27 |
2022-11-08 |
Development Center For Biotechnology |
Light chain-bridged bispecific antibody
|
AR090549A1
(es)
*
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
WO2013165940A1
(en)
*
|
2012-05-01 |
2013-11-07 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
US9163090B2
(en)
*
|
2012-05-07 |
2015-10-20 |
Cellerant Therapeutics, Inc. |
Antibodies specific for CLL-1
|
US20150203591A1
(en)
|
2012-08-02 |
2015-07-23 |
Regeneron Pharmaceuticals, Inc. |
Mutivalent antigen-binding proteins
|
CN104379169A
(zh)
|
2012-08-14 |
2015-02-25 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
WO2014043403A1
(en)
|
2012-09-12 |
2014-03-20 |
Agensys, Inc. |
Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
JP6471095B2
(ja)
|
2012-09-27 |
2019-02-20 |
メルス ナムローゼ フェンノートシャップ |
T細胞エンゲージャーとしての二重特異性IgG抗体
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
EP2774624A1
(en)
|
2013-03-04 |
2014-09-10 |
Heidelberg Pharma GmbH |
Amatoxin derivatives
|
US9821074B2
(en)
|
2013-03-13 |
2017-11-21 |
Genentech, Inc. |
Pyrrolobenzodiazepines and conjugates thereof
|
WO2014153002A1
(en)
|
2013-03-14 |
2014-09-25 |
The California Institute For Biomedical Research |
Bispecific antibodies and uses thereof
|
WO2014141152A2
(en)
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Low concentration antibody formulations
|
CA2913069A1
(en)
|
2013-05-28 |
2014-12-04 |
Numab Ag |
Novel antibodies
|
SG10201710727UA
(en)
|
2013-05-28 |
2018-02-27 |
Dcb Usa Llc |
Antibody locker for the inactivation of protein drug
|
TWI725931B
(zh)
|
2013-06-24 |
2021-05-01 |
美商建南德克公司 |
抗fcrh5抗體
|
KR20160029128A
(ko)
|
2013-07-12 |
2016-03-14 |
자임워크스 인코포레이티드 |
이중특이적 cd3 및 cd19 항원 결합 구조체
|
AU2014307080B2
(en)
|
2013-08-12 |
2018-06-07 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
AU2014343636A1
(en)
|
2013-11-04 |
2016-06-02 |
Glenmark Pharmaceuticals S.A. |
Production of T cell retargeting hetero-dimeric immunoglobulins
|
CR20160271A
(es)
|
2013-12-16 |
2016-12-02 |
Genentech Inc |
Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
|
MX2016007578A
(es)
|
2013-12-16 |
2016-10-03 |
Genentech Inc |
Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
|
WO2015095223A2
(en)
|
2013-12-16 |
2015-06-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
CN105848685B
(zh)
|
2013-12-16 |
2020-09-22 |
健泰科生物技术公司 |
拟肽化合物及其抗体药物偶联物
|
SI3083689T1
(sl)
|
2013-12-17 |
2020-10-30 |
Genentech, Inc. |
Anti-CD3 protitelesa in načini uporabe
|
JP2017507900A
(ja)
|
2013-12-17 |
2017-03-23 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及び抗her2抗体を使用してher2陽性がんを治療する方法
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
GB201409653D0
(en)
|
2014-05-30 |
2014-07-16 |
Stell Dr Anneliese |
Pyrrolobenzodiazepine therapeutic agents
|
AU2015299163B2
(en)
|
2014-08-04 |
2019-07-18 |
F. Hoffmann-La Roche Ag |
Bispecific T cell activating antigen binding molecules
|
WO2016019969A1
(en)
|
2014-08-08 |
2016-02-11 |
Ludwig-Maximilians-Universität München |
Subcutaneously administered bispecific antibodies for use in the treatment of cancer
|
WO2016036678A1
(en)
|
2014-09-02 |
2016-03-10 |
Medimmune, Llc |
Formulations of bispecific antibodies
|
PE20170670A1
(es)
|
2014-09-12 |
2017-06-06 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
EP3235820A1
(en)
|
2014-09-17 |
2017-10-25 |
Genentech, Inc. |
Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
KR102614189B1
(ko)
|
2014-11-17 |
2023-12-18 |
리제너론 파아마슈티컬스, 인크. |
Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
|
CA2969689A1
(en)
|
2014-12-03 |
2016-06-09 |
Genentech, Inc. |
Quaternary amine compounds and antibody-drug conjugates thereof
|
AR102918A1
(es)
|
2014-12-05 |
2017-04-05 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
US10544220B2
(en)
|
2015-01-08 |
2020-01-28 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
WO2016191750A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
WO2016205200A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cll-1 antibodies and methods of use
|
KR20180023952A
(ko)
|
2015-06-16 |
2018-03-07 |
제넨테크, 인크. |
FcRH5에 대한 인간화 및 친화도 성숙 항체 및 사용방법
|
WO2016204966A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
MX2017016169A
(es)
|
2015-06-17 |
2018-08-15 |
Genentech Inc |
Anticuerpos anti-her2 y metodos de uso.
|
EP3408671B1
(en)
|
2016-01-25 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Methods for assaying t-cell dependent bispecific antibodies
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|